Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

AmplifyBio Secures $50M in Debt Financing With Hercules Capital to Accelerate Business Plan

AmplifyBio announces $50M in debt financing to accelerate the expansion of its service offering, supporting the rapid, safe development of next-generation therapeutics

AmplifyBio
AmplifyBio

AmplifyBio

WEST JEFFERSON, Ohio - January 12, 2023 - (Newswire.com)

AmplifyBio announced that it had augmented its balance sheet with non-dilutive debt financing, whereby it may borrow a principal amount of up to $50 million from Hercules Capital, Inc. (NYSE: HTGC). The move allows AmplifyBio to continue investing in its strategic plan, including the rapid growth of sites, technology, and service offerings planned for the coming 18 to 24 months.

Securing this funding comes a mere 18 months after AmplifyBio's launch as a commercially focused spinoff from Battelle. Since launch, AmplifyBio has hired over 150 additional personnel, built a state-of-the-art analytics laboratory on its West Jefferson, Ohio, campus, and acquired a second site in South San Francisco dedicated to the robust characterization of advanced therapies. The company will soon open a new location in New Albany, Ohio, to add technologies and partnerships that further expedite the safe commercialization of novel therapeutics.  

"The newly obtained funding that further bolsters our strong balance sheet will augment the ongoing platform development initiatives at the South San Francisco and the Ohio sites. In both places, we are adding service capabilities focused on the characterization that is essential for better understanding the safety and efficacy of next-generation therapeutics. These funds will allow us to securely accelerate our business plan to deliver services that employ a technology and partnership-integrated sandbox approach to next-generation development," said J. Kelly Ganjei, CEO, AmplifyBio.

"Hercules is proud to partner with AmplifyBio and support its mission of creating next-generation platforms, tools, and services to amplify and accelerate the development of new therapies and vaccines," said Bryan Jadot, Senior Managing Director and Life Sciences Group Head at Hercules Capital. "This substantial capital commitment from Hercules aims to help AmplifyBio achieve its growth objectives and to continue to advance its capabilities."

Since its launch, AmplifyBio has sought to build an environment dedicated to accelerating advanced therapies with a focus on robust drug characterization before and during preclinical safety assessments. Those assessments now include a combination of genetic and phenotypic assays to identify biologic characteristics that help ensure developers have compositional and functional control of a product, thereby providing a complete system understanding of drug function and efficacy, particularly immunologically. 

About AmplifyBio

AmplifyBio is a leading preclinical CRO focused on toxicology, safety, and pharmacology testing to advance therapeutics for the betterment of human health. Spun out of Battelle in May of 2021, AmplifyBio's mission is to continue to provide exceptional CRO study services in an agile environment suited to commercial goals and expand analytic capabilities to serve the dynamic needs of advanced therapy development. Clients of AmplifyBio enjoy the peace of mind that comes from decades of experience in GLP and non-GLP study design and execution, combined with rapid investment in technology, expertise, and infrastructure that together provide the critical components of a reliable, preclinical partnership. 


Contact Information:
Buse Kayar
buse@newswire.com

Kimberly LaPointe
Director of Marketing
klapointe@amplify-bio.com
19047385897


Press Release Service by Newswire.com

Original Source: AmplifyBio Secures $50M in Debt Financing With Hercules Capital to Accelerate Business Plan
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.